Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPβ
Catabolism of the essential amino acid tryptophan is a key metabolic pathway contributing to the immunosuppressive tumor microenvironment and therefore a viable drug target for cancer immunotherapy. In addition to the rate-limiting enzyme indoleamine-2,3-dioxygenase-1 (IDO1), tryptophan catabolism v...
Main Authors: | Takumi Kudo, Mirja T. Prentzell, Soumya R. Mohapatra, Felix Sahm, Zhongliang Zhao, Ingrid Grummt, Wolfgang Wick, Christiane A. Opitz, Michael Platten, Edward W. Green |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00657/full |
Similar Items
-
Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors
by: Michael ePlatten, et al.
Published: (2015-01-01) -
The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells.
by: Christiane A Opitz, et al.
Published: (2011-01-01) -
Hypoxia Inducible Factor 1α Inhibits the Expression of Immunosuppressive Tryptophan-2,3-Dioxygenase in Glioblastoma
by: Soumya R. Mohapatra, et al.
Published: (2019-12-01) -
TDoA UWB Positioning with Three Receivers Using Known Indoor Features
by: KATAYAMA, Masaaki, et al.
Published: (2010) -
TDO Promotes Hepatocellular Carcinoma Progression
by: Li S, et al.
Published: (2020-06-01)